Protein Klotho and FGF23 fibroblasts growth factor as markers of chronic renal disease
Journal Title: Нирки - Year 2017, Vol 6, Issue 3
Abstract
Chronic kidney disease (CKD) is a global public health problem in the world. Research scientists are aimed at finding new biomarkers for CKD. Such biomarkers are α-Klotho soluble protein and fibroblast growth factor (FGF23). It was shown that the expression of Klotho protein decreases progressively as the progression of CKD and reaches low or undetectable values at the terminal stage of kidney disease. Unlike Klotho, FGF23 fibroblast growth factor increases in the early stages of CKD and serves as a predictor of an unfavorable clinical outcome. Klotho and FGF23 protein levels are early, sensitive and specific diagnostic biomarkers in CKD and are of diagnostic value for predicting complications of kidney disease.
Authors and Affiliations
A. A. Melnik
Keywords
Related Articles
- EP ID EP219376
- DOI 10.22141/2307-1257.6.3.2017.109027
- Views 93
- Downloads 0
Drug Treatment of Diabetic Nephropathy on Hyperfiltration Stage
In the article deals with the problem of early clinical diagnosis markers of diabetic kidney disease, namely hyperfiltration and renal functional reserve, reflecting first structural and functional changes in patients w...
Kidney Transplantation on Children
.
Guideline Summary NGC (2016): Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
National Institute for Health and Care Excellence (NICE) June 14, 2016 – Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR) External Web Site Policy: The U.S. Food and Drug Administration (FDA) ha...
Nifuratel Application in Therapy of Urinary Tract Infections
Increased multidrug resistance of extended-spectrum beta-lactamases (ESBLs) compromises the efficacy of treatment of urinary tract infections. The objective of this study is to determine the prevalence of ESBL-producing...
American Diabetes Association. Standards of Medical Care in Diabetes — 2017
.